RxDoctor Payments Data

Mariana Cruz Manzano, MD

Dermatology · Caguas, PRNPI 1760821565

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,556 of the $1,917 with a category attached, or 81.1%. 11 manufacturers reported payments, led by Johnson & Johnson at 30.9% of the total. That places this record below the midpoint for dermatology clinicians in PR, where the typical reported total is $1,906.

$1,917in general payments, 2019–2025

Across 69 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$592
  • AbbVie$381
  • Sanofi$339
  • Eli Lilly Export S.A. Puerto Rico Branch$208
  • Amgen$105
  • Sanofi-aventis U.S. LLC$100
  • plus $193 from 5 others

What the payments were for

  • Food & beverage$1,55681%
  • Education$36119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,917 in reported general payments places this provider in the 50th percentile of 108 dermatology providers in Puerto Rico.

See all dermatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$20,809
Medicare patients
69
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa26$523,787
OtezlaApremilast20$96,803
Dupixent PenDupilumab14$53,304
Clobetasol Propionate407$25,644
Betamethasone Dipropionate261$12,086
Ketoconazole514$11,457
Calcipotriene81$9,458
Acitretin11$8,297
Ciclopirox192$7,263
Tacrolimus42$4,500
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc111$3,934
Metronidazole48$3,199
Mometasone Furoate123$3,176
Betamethasone Valerate70$2,747
Triamcinolone Acetonide283$2,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$105$96,80320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 108 dermatology providers in Puerto Rico.

Other dermatology in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →